Login to Your Account

Sienna seeks $74.8M IPO to improve treatments for multiple skin conditions

By Michael Fitzhugh
Staff Writer

Wednesday, July 5, 2017

Sienna Biopharmaceuticals Inc., a California-based dermatology company developing small-molecule topical therapies for people with a variety of common skin issues, is seeking gross proceeds of up to $74.8 million in an IPO.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription